Streetbeat News

FENC

Fennec Pharmaceuticals Inc.

https://www.fennecpharma.com

Industry

Biotechnology

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Open

4.69

Mkt cap

119M

Volume

272K

High

4.69

P/E Ratio

62.29

52-wk high

11.92

Low

4.21

Div yield

N/A

52-wk low

4.09

HC Wainwright & Co. has maintained its Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) but lowered the price target from $18 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:10 am

Alibaba Group Holding Limited (NYSE:BABA) shares fell by around 7% following mixed Q1 financial results. Other stocks experienced significant movements, with notable gainers including Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) and losers like Scorpius Holdings, Inc. (NASDAQ:SCPX).

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 5:30 pm

Fennec Pharmaceuticals' shares are trading lower following the announcement of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 5:20 pm

Fennec Pharmaceuticals (NASDAQ:FENC) reported Q1 2024 earnings of $0.41 per share, surpassing the $0.26 estimate, marking a 278.26% increase from last year. Sales reached $25.377M, beating the $18.876M estimate, a 1.41K% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:27 am

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) and raises the price target from $17 to $18.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 10:22 am

Numerous companies are scheduled to report their earnings on March 21, 2024, covering a wide range of industries from technology to healthcare. The reports include a mix of expected quarterly earnings and losses, with notable companies such as Welltower, Academy Sports, Exscientia, Direxion Daily CSI China Internet Index Bull 2X Shares, and Winnebago Industries among those reporting before the bell. After the bell, companies like Lululemon Athletica, Nike, FedEx, and Intellicheck will report, providing insights into their financial health and performance.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 10:15 am

Fennec Pharmaceuticals reported Q4 earnings with a loss of $(0.10) per share, missing the $(0.02) estimate by 400%, but showed a 61.54% improvement from last year. Sales reached $9.73M, exceeding the $8.67M estimate by 12.28% and marking a 534.20% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 10:02 am

Fennec Pharmaceuticals (NASDAQ:FENC) is scheduled to release its quarterly earnings report on Thursday, 2024-03-21, with an expected EPS of $-0.02. Analysts and investors are keen on not just the earnings beat but also the company's guidance for future growth. Historically, FENC has shown a mixed performance in beating EPS estimates, with the last quarter showing a beat that led to a 2.51% increase in share price. Over the last year, FENC shares have risen by 50.54%, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 5:01 pm

Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) and raises the price target from $17 to $18.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 7:31 pm

Fennec Pharmaceuticals' stock is trading higher following the announcement of an exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 3:50 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.